Education
About Us
Working with TipRanks
Follow Us
Immuron Limited (DE:ANW)
FRANKFURT:ANW
ANW Stock Chart & Stats
€0.01
€0.00(0.00%)
At close: 4:00 PM EST
€0.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.01 - €0.05
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€5.67M
Enterprise Value€5.02M
Total Cash (Recent Filing)€5.87M
Total Debt (Recent Filing)€117.13K
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Mar 04, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding326,653,600
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.75
Price to Sales (P/S)1.93
P/FCF Ratio-2.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Established Commercial ProductHaving an marketed OTC product (Travelan) provides a durable revenue base and direct consumer distribution experience. This supports recurring sales, retailer/distributor relationships and cash generation potential that can fund development and validate the oral immunotherapy business model over the medium term.
Oral Gut‑targeted Platform & PipelineA focused platform in orally delivered polyclonal antibodies creates a defensible niche with applicability across gastrointestinal and immune-related indications. Pipeline assets and platform leverage can enable multiple commercial programs or partnerships, supplying long-term growth optionality beyond the single marketed product.
Very Low Financial LeverageExtremely low leverage reduces solvency risk and gives strategic flexibility to fund R&D or commercial expansion through equity or operating cash rather than debt. This balance-sheet conservatism is a durable strength in biotech, where clinical timelines and financing needs can be unpredictable.
Bears Say
Negative Cash GenerationOngoing negative operating and free cash flow imply persistent cash burn that will require external financing or dilution to sustain operations and trials. This constrains long-term investment in commercialization or clinical programs and raises execution risk if capital markets tighten.
Unprofitable OperationsSustained negative EBIT and net margins mean the company is not converting revenue into profits, limiting internal reinvestment and reducing resilience to setbacks. Without a clear path to margin improvement, reliance on financing and partnerships will persist, increasing strategic vulnerability.
Clinical & Scale DependencyMaterial growth depends on clinical success and regulatory approvals for pipeline candidates; this creates protracted binary risk. Combined with a very small operating base, the company may face scalability, commercialization execution and funding challenges if trials require additional investment or timelines slip.
Immuron Limited News
ANW FAQ
What was Immuron Limited’s price range in the past 12 months?
Immuron Limited lowest stock price was €0.01 and its highest was €0.05 in the past 12 months.
What is Immuron Limited’s market cap?
Immuron Limited’s market cap is €5.67M.
When is Immuron Limited’s upcoming earnings report date?
Immuron Limited’s upcoming earnings report date is Mar 04, 2026 which is in 13 days.
How were Immuron Limited’s earnings last quarter?
Immuron Limited released its earnings results on Sep 02, 2025. The company reported €0 earnings per share for the quarter, the consensus estimate of N/A by €0.
Is Immuron Limited overvalued?
According to Wall Street analysts Immuron Limited’s price is currently Overvalued.
Does Immuron Limited pay dividends?
Immuron Limited does not currently pay dividends.
What is Immuron Limited’s EPS estimate?
Immuron Limited’s EPS estimate is 0.
How many shares outstanding does Immuron Limited have?
Immuron Limited has 326,653,600 shares outstanding.
What happened to Immuron Limited’s price movement after its last earnings report?
Immuron Limited reported an EPS of €0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Immuron Limited?
Currently, no hedge funds are holding shares in DE:ANW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immuron Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.31%
12-Months-Change
Fundamentals
Return on Equity
-49.96%
Trailing 12-Months
Asset Growth
-41.64%
Trailing 12-Months
Company Description
Immuron Limited
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III registration trial to reduce the risk of contracting travelers' diarrhea in the United States, and Phase II field trial for Travelers' Diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in Phase I/IIa clinical trial for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
Technical Analysis
Noxopharm Ltd.
―
Avecho Biotechnology Limited
―
AdAlta Ltd.
―
Anatara Lifesciences Ltd
―
Neuroscientific Biopharmaceuticals Ltd.
―